Physician profile
Atul Madan
NPI 1528153236
$3,133.39
in general payments reported to CMS, 2019-2025
24 companies · $816 in 2025
The $816 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $236 · 2021: $277 · 2022: $413 · 2023: $344 · 2024: $465 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $603.82 | 2019-2025 | Impella |
| Medtronic, INC. | $344.47 | 2021-2025 | Hawkone, Resolute Onyx, Symplicity G3 |
| Pfizer INC. | $264.40 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $233.42 | 2020-2025 | Lifevest |
| Abbott Laboratories | $219.65 | 2020-2023 | Confirm Rx |
| Novartis Pharmaceuticals Corporation | $193.73 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $191.69 | 2022-2025 | Optimizer, Optimizer |
| Astellas Pharma US INC | $143.26 | 2020-2021 | |
| Boston Scientific Corporation | $142.61 | 2019-2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $105.92 | 2023 | |
| Merck Sharp & Dohme LLC | $96.48 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $93.29 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $86.18 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $75.73 | 2019-2025 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $67.02 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $46.50 | 2024-2025 | Nexletol |
| Amgen INC. | $43.93 | 2019-2020 | |
| Medtronic Vascular, INC. | $39.55 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $35.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.11 | 2025 | |
| Genzyme Corporation | $22.99 | 2020 | |
| Portola Pharmaceuticals, LLC | $17.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Madan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.